Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SAB-142
High Dose SAB-142 · 1 trial · 1 indication
This is a measure of endogenous insulin production and β cell function (change from baseline in C-peptide ln \[AUC+1\] at 12 months)
This is a measure of endogenous insulin production and β-cell function (change from baseline in C-peptide ln \[AUC+1\] at 24 months versus control).
| Arm | Type | Description |
|---|---|---|
| High Dose SAB-142 | EXPERIMENTAL | Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. Part C: Long-term efficacy and safety study. Participants continue treatment according to assigned induction dose. Eligible participants who received placebo in Part B and enter Part C will be randomised to active SAB-142 treatment. |
| Low Dose SAB-142 | EXPERIMENTAL | Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. Part C: Long-term efficacy and safety study. Participants continue treatment according to assigned induction dose. Eligible participants who received placebo in Part B and enter Part C will be randomised to active SAB-142 treatment. |
| Placebo | PLACEBO_COMPARATOR | Part B: This is a double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. |
| Name | Type | Description |
|---|---|---|
| High Dose SAB-142 | DRUG | High Dose SAB-142 |
| Low Dose SAB-142 | DRUG | Low Dose SAB-142 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Participant and/or appropriate legal guardian for participants below the legal age of consent must have given written informed consent and/or assent according to local, regional and/or country specific guidance before any study-related activities are carried out and must be a...
High Dose SAB-142 is an investigational therapy being studied for Type 1 Diabetes (T1D). It is designed to arrest the progression of the disease by targeting thymocytes, a type of protein. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
High Dose SAB-142 targets thymocyte protein, which is involved in the immune response associated with Type 1 Diabetes. By modulating this target, the therapy aims to preserve pancreatic beta-cell function and slow disease progression. This mechanism is being evaluated in clinical trials for T1D.
High Dose SAB-142 is being developed by SAB Biotherapeutics, Inc., a biopharmaceutical company traded under the ticker symbol SABS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for Type 1 Diabetes.
High Dose SAB-142 is currently in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 trial is recruiting participants to assess its ability to arrest the progression of Type 1 Diabetes.
High Dose SAB-142 is being studied in a Phase 2 trial with the identifier NCT07187531. This randomized, double-blind, placebo-controlled study is recruiting 159 participants with Type 1 Diabetes across multiple countries, including the United States, Australia, and several European nations.
Yes, High Dose SAB-142 is also known as SAB-142. Both names refer to the same investigational drug being developed by SAB Biotherapeutics for the treatment of Type 1 Diabetes. The drug is currently in Phase 2 clinical trials.